INmune Bio, Inc.
INMB
$1.98
-$0.03-1.49%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | 50.00K | 0.00 | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | 50.00K | 0.00 | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | 50.00K | 0.00 | -- | -- |
SG&A Expenses | 2.25M | 2.32M | 2.11M | 2.22M | 2.81M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 8.06M | 9.96M | 9.47M | 12.29M | 9.87M |
Operating Income | -8.06M | -9.91M | -9.47M | -12.29M | -9.87M |
Income Before Tax | -24.46M | -9.74M | -9.22M | -12.09M | -9.75M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -24.46M | -9.74M | -9.22M | -12.09M | -9.75M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -24.46M | -9.74M | -9.22M | -12.09M | -9.75M |
EBIT | -8.06M | -9.91M | -9.47M | -12.29M | -9.87M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -1.05 | -0.43 | -0.41 | -0.60 | -0.50 |
Normalized Basic EPS | -0.21 | -0.27 | -0.26 | -0.37 | -0.32 |
EPS Diluted | -1.05 | -0.43 | -0.41 | -0.60 | -0.50 |
Normalized Diluted EPS | -0.21 | -0.27 | -0.26 | -0.37 | -0.32 |
Average Basic Shares Outstanding | 23.30M | 22.50M | 22.25M | 20.19M | 19.31M |
Average Diluted Shares Outstanding | 23.30M | 22.50M | 22.25M | 20.19M | 19.31M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |